Skip to main content

Table 4 Overall and subgroups meta-analysis of H19 rs217727 (C > T) polymorphism and cancer risk

From: Association between lncRNA H19 rs217727 polymorphism and the risk of cancer: an updated meta-analysis

Overall and subgroups

NO.

T versus C

TT versus CC

CT versus CC

CT + TT versus CC

TT versus CT + CC

OR (95% CI)

PQ

I2(%)

OR (95% CI)

PQ

I2(%)

OR (95% CI)

PQ

I2(%)

OR (95% CI)

PQ

I2(%)

OR (95% CI)

PQ

I2(%)

Total

17

1.16 (1.06, 1.27)

0

75.7

1.29 (1.06, 1.56)

0

71.6

1.15 (1.01, 1.31)

0

75.4

1.20 (1.05, 1.36)

0

76.5

1.22 (1.02, 1.45)

0

70.6

Ethnicity

 Asians

16

1.18 (1.08, 1.29)

0

75.3

1.32 (1.09, 1.59)

0

72.1

1.18 (1.03, 1.34)

0

75.9

1.23 (1.08, 1.39)

0

76.4

1.24 (1.04, 1.47)

0

71.4

 Caucasians

1

0.74 (0.52, 1.05)

NA

NA

0.45 (0.13, 1.50)

NA

NA

O.74 (0.49, 1.14)

NA

NA

0.71 (0.47, 1.08)

NA

NA

0.50 (0.15, 1.66)

NA

NA

Method

 TaqMan

9

1.07 (0.98, 1.17)

0.01

60.6

1.12 (0.92, 1.36)

0.01

63.2

1.12 (0.96, 1.31)

0

74.1

1.12 (0.98, 1.29)

0

72.6

1.06 (0.87, 1.31)

0

70.8

 MassArray

2

1.36 (1.16, 1.60)

0.28

13.8

1.96 (1.39, 2.75)

0.53

0

1.29 (1.05, 1.57)

0.32

0.4

1.39 (1.14, 1.71)

0.29

10.9

1.75 (1.26, 2.42)

0.66

0

 PCR-RFLP

3

1.44 (0.68, 3.05)

0

90.9

4.14 (0.21, 80.14)

0

89

1.32 (0.66, 2.64)

0

83.7

1.45 (0.63, 3.35)

0

89.4

3.60 (0.26, 49.72)

0

86.2

 Others

3

1.17 (1.07, 1.28)

0.4

0

1.33 (1.11, 1.61)

0.42

0

1.01 (0.68, 1.51)

0

86

1.12 (0.84, 1.49)

0.01

77

1.33 (1.12, 1.57)

0.83

0

Cancer type

 Breast cancer

5

1.29 (1.02, 1.62)

0

86.8

1.56 (0.95, 2.56)

0

83

1.15 (0.84, 1.55)

0

84.2

1.27 (0.94, 1.71)

0

85.7

1.48 (0.98, 2.26)

0

80.3

 Bladder cancer

3

1.01 (0.82, 1.25)

0.1

56.8

0.80 (0.40, 1.61)

0.06

64

1.20 (0.64, 2.23)

0

90.1

1.13 (0.68, 1.88)

0

85.9

0.63 (0.22, 1.80)

0

85.1

 Digestive system cancera

3

1.02 (0.82, 1.26)

0.04

81.6

1.05 (0.68, 1.62)

0.01

79.8

1.00 (0.79, 1.26)

0.08

61

1.01 (0.77, 1.34)

0.02

76.1

1.03 (0.76, 1.41)

0.04

68.5

 Osteosarcoma

1

1.27 (0.98, 1.66)

NA

NA

1.29 (0.61, 2.71)

NA

NA

1.53 (1.07, 2.19)

NA

NA

1.50 (1.05, 2.12)

NA

NA

1.04 (0.50, 2.13)

NA

NA

 Cervical cancer

1

1.53 (1.17, 2.02)

NA

NA

2.35 (1.21, 4.57)

NA

NA

1.50 (1.05, 2.16)

NA

NA

1.62 (1.15, 2.29)

NA

NA

1.98 (1.04, 3.78)

NA

NA

 Oral squamous cell carcinoma

2

1.26 (1.11, 1.42)

0.72

0

1.63 (1.25, 2.12)

0.42

0

1.25 (1.04, 1.50)

0.65

0

1.32 (1.11, 1.57)

0.8

0

1.42 (1.07, 1.88)

0.24

28.1

 Lung cancer

2

1.17 (1.03, 1.33)

0.73

0

1.44 (1.07, 1.94)

0.27

19.4

1.08 (0.84, 1.39)

0.18

44.4

1.15 (0.97, 1.37)

0.47

0

1.37 (0.89, 2.11)

0.08

67.6

Source ofcontrols

 Population-based

8

1.16 (0.98, 1.38)

0

86.5

1.36 (0.96, 1.93)

0

82.4

1.08 (0.87, 1.33)

0

80.9

1.15 (0.92, 1.43)

0

84.7

1.30 (0.98, 1.73)

0

77.4

 Hospital-based

9

1.15 (1.07, 1.24)

0.18

29.6

1.29 (1.07, 1.55)

0.09

41.4

1.21 (1.03, 1.45)

0

68.5

1.23 (1.07, 1.42)

0.02

57.4

1.16 (0.93, 1.46)

0

64.7

Case sample size

 ≥ 500

13

1.13 (1.04, 1.22)

0

67.1

1.27 (1.08, 1.49)

0

63.6

1.08 (0.96, 1.20)

0

65.2

1.13 (1.01, 1.25)

0

66.4

1.25 (1.08, 1.41)

0.01

56.4

 <  500

4

1.36 (0.83, 2.23)

0

87.1

2.29 (0.31, 16.97)

0

88.2

1.57 (0.88, 2.80)

0

83.9

1.60 (0.87, 2.92)

0

85.8

1.77 (0.23, 13.44)

0

89

  1. aIncluding colorectal cancer, gastric cancer and pancreatic cancer